RUNX3 is down‐regulated in glioma by Myc‐regulated miR‐4295. Issue 3 (12th January 2016)

• Record Type: Journal Article
• Authors: Li, Xinxing; Zheng, Jihui; Diao, Hongyu; Liu, Yunhui
• Is Part Of: Journal of cellular and molecular medicine. Volume 20:Issue 3(2016)
• Page Start: 518
• Page End: 525
• Publication Date: 2016-01-12
• Subjects: glioma -- miR‐4295 -- RUNX3 -- N‐myc; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.12736
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: MicroRNAs are increasingly reported as tumour suppressors that regulate gene expression after transcription. Our results demonstrated that miR‐4295 is overexpression in glioma tissues and its level is significantly correlated with clinical stage. We also found that miR‐4295 inhibited the cell G0/G1 arrest and apoptosis leading to promoted cell proliferation and activity. The murine modelling study revealed that female nude mice injected with U87/anti‐miR‐4295 exhibit subcutaneous tumours in the right groin. Compared with anti‐NC, the tumour volume was significantly decreased in anti‐miR‐4295 treatment group. Furthermore, we confirmed miR‐4295 mediates the expression of RUNX3 by targeting its 3′untranslation region. In addition, N‐myc protein also could bind to the promoter of pri‐miR‐4295 and inhibit the expression of RUNX3 in glioma cells. These results validate a pathogenetic role of a miR‐4295 in gliomas and establish a potentially regulatory and signalling pathway involving N‐myc/miR‐4295/RUNX3 in gliomas.